Lyfgenia (Lovotibeglogene Autotemcel)

Lovotibeglogene autotemcel is a one-time gene therapy for sickle cell disease. Doctors collect a person's own blood stem cells, add a working copy of a hemoglobin gene in a lab, and give the cells back through an infusion into a vein. The new cells help the body make healthier red blood cells that are less likely to sickle.

Brand names:Lyfgenia
Medication

What people taking Lyfgenia (Lovotibeglogene Autotemcel) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lyfgenia (Lovotibeglogene Autotemcel) for Sickle Cell Disease?

NameHow it went

About Lyfgenia (Lovotibeglogene Autotemcel)

What It's For

Lyfgenia (lovotibeglogene autotemcel) is a one-time gene therapy for sickle cell disease in people 12 and older who have had vaso-occlusive events. These are the episodes in which sickled red blood cells block small blood vessels, causing pain crises, acute chest syndrome (a lung complication) or sudden pooling of blood in the spleen or liver. Lyfgenia is made individually for each person from their own blood-forming stem cells. Because treatment involves high-dose chemotherapy and a stem cell transplant, it is a major decision usually considered by people whose disease keeps causing serious crises, and only after a specialist center confirms that a transplant is appropriate for them. Other options include hydroxyurea, regular transfusions, a stem cell transplant from a closely matched donor, often a brother or sister, and another gene therapy, Casgevy (exagamglogene autotemcel), which edits the person's existing genes rather than adding a new one. People who also carry alpha-thalassemia trait with two missing alpha-globin genes may develop lasting anemia after Lyfgenia and need ongoing transfusions. It has not been studied in people missing more than two of these genes, so genetic testing is part of deciding whether it fits.

How It Works

Sickle cell disease comes from a change in the gene for beta-globin, one of the building blocks of hemoglobin, the protein that carries oxygen in red blood cells. The altered hemoglobin, called hemoglobin S, clumps into stiff strands after it releases oxygen. That bends red cells into a rigid sickle shape, so they break down early and can jam small blood vessels. Lyfgenia adds a working, slightly modified copy of the beta-globin gene to a person's own stem cells. The cells are collected and sent to a manufacturing lab, where a disabled virus that cannot cause infection (a lentiviral vector) carries the new gene into them. After chemotherapy clears space in the bone marrow, the modified cells are infused back, settle in the marrow and begin producing red blood cells that contain a new form of hemoglobin. This hemoglobin carries oxygen much like normal adult hemoglobin, lowers the share of hemoglobin S and is designed to physically block the clumping that causes sickling. Because the cells come from the person's own body, there is no need to find a donor and, in the studies, no long-term anti-rejection medicine was needed.

Dosage & Administration

Lyfgenia is not a pill or a regular prescription. It is a single infusion given at a specialized treatment center, at the end of a process that stretches over several months. Preparation begins with scheduled red blood cell transfusions, usually monthly for at least two months, to lower hemoglobin S and reduce the chance of a crisis during the next steps. Some sickle cell medicines are paused beforehand (see Interactions & Warnings). Stem cells are then coaxed out of the bone marrow into the bloodstream with a medicine called plerixafor and collected by apheresis, in which a machine draws blood, keeps the stem cells and returns the rest. Most people in the studies needed one or two collection cycles, each typically lasting two days. Some of the collected cells are frozen as a back-up in case the treated cells do not take hold. Once the finished product has arrived at the center, the person receives four days of busulfan, a strong chemotherapy given through a central line (a larger IV placed in a chest or neck vein) that wipes out the existing bone marrow. At least 48 hours later, Lyfgenia is infused through a vein from one to four bags, each over less than 30 minutes. The dose is set from the number of modified cells per kilogram of body weight. If manufacturing fails or too few cells are produced, another round of collection may be needed.

Side Effects

Most of the difficult side effects come from the busulfan chemotherapy and the transplant process rather than from the modified cells themselves. Busulfan drives blood counts very low for weeks. In the main study, most people had severe drops in platelets (the cells that help blood clot) and in infection-fighting white cells, and nearly half had a fever while their white cell counts were low, a sign of possible serious infection. Severe mouth sores (stomatitis) affected about 7 in 10 people, and nausea, poor appetite, sore throat and raised liver test results were also common. White cells recovered at a median of about three weeks after the infusion. Platelets took longer, a median of about five weeks, and two people needed more than 100 days. Until platelets recover, bleeding is more likely, so unusual bleeding or bruising should be reported to the transplant team right away, and frequent platelet checks continue until counts are back up. The stem cell collection step can itself set off a sickle cell crisis; in the study about 1 in 7 people had a crisis serious enough to count as a serious adverse event. Allergic reactions during the infusion, caused by preservatives in the bag (DMSO and dextran 40), are possible and are watched for by the infusion team. In the study, two people had mild reactions, a hot flush and a drop in blood pressure, that resolved.

Interactions & Warnings

Lyfgenia carries a boxed warning, the FDA's most prominent type of warning, for blood cancer. Two people treated with an earlier version, made by a different manufacturing process and transplant procedure, developed acute myeloid leukemia (AML) and died, and one person with alpha-thalassemia trait developed myelodysplastic syndrome (MDS), a bone marrow disorder that can turn into leukemia. Several factors may contribute: sickle cell disease on its own raises the risk of blood cancers, the chemotherapy and the strain of rebuilding the marrow may add to it, and inserting a gene carries a theoretical risk of switching on cancer-causing genes. For this reason, monitoring is lifelong: a complete blood count at least every 6 months for at least 15 years, plus tests at 6 and 12 months that check where the new gene has landed in the cells. Busulfan can cause permanent infertility, so options for preserving fertility are worth discussing before starting. Lyfgenia is not given during pregnancy. A negative pregnancy test is required before cell collection, before chemotherapy and before the infusion, and effective contraception is recommended from the start of collection through at least 6 months after the infusion. Several medicines have to be paused. Hydroxyurea and other disease-modifying sickle cell medicines, such as L-glutamine and crizanlizumab, are stopped at least 2 months before cell collection. HIV prevention medicines are stopped at least a month before collection (longer for long-acting forms) because they can interfere with manufacturing. Iron-removing medicines (chelators) are paused around collection and chemotherapy, and those that lower blood counts, such as deferiprone, are not restarted for at least 6 months afterward. After treatment, HIV tests based on PCR (a test that detects genetic material) can come back falsely positive because of the gene-delivery vector, so a different type of HIV test should be used. People treated with Lyfgenia should never donate blood, organs, tissues or cells.

What to Expect

The first weeks after the infusion are spent under close watch by the transplant team while blood counts recover. Any blood products needed in the first 3 months must be specially treated (irradiated), and vaccinations are restarted on the schedule used after a stem cell transplant. In the main study, 28 of 32 people (88%) had no vaso-occlusive events between 6 and 18 months after the infusion, and 30 of 32 (94%) had no severe ones, such as crises needing hospital care. Most people (86%) made enough of the new hemoglobin to meet the study's definition of response, and kept it once they did. Benefit was not complete for everyone: 4 people later had vaso-occlusive events again, and about half were still prescribed opioids for sickle cell or other pain in the following period. These results come from a small study of 36 treated people with no comparison group and follow-up of roughly one to five years, so how long the benefit lasts over decades is not yet known. Follow-up visits and blood tests continue for many years, and people are encouraged to join a long-term safety study.

Questions to Ask Your Doctor

  1. 1.Given my crisis history, organ health and alpha-globin genes, am I a good candidate, and how does Lyfgenia compare with Casgevy, a donor transplant or continuing my current treatment?
  2. 2.What are my options for preserving fertility before busulfan, and what would that involve?
  3. 3.How long will the whole process take, how much time will I need to spend at or near the treatment center, and what happens if manufacturing fails?
  4. 4.Who will coordinate my blood cancer monitoring over the next 15 years or more, and what results would raise concern?
  5. 5.How would my pain care and other sickle cell treatments change after the infusion?

Last reviewed • Oct 2026

Educational content, not medical advice.